Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia

被引：0
|
作者：
Fan Yang
Li Zhang
Bei-Bei Zhao
Jing-Liao Zhang
Xi-Ting Liu
Xue Li
Bo-Hao Tang
Yue Zhou
Xin-Mei Yang
John van den Anker
Xiao-Fan Zhu
Wei Zhao
机构：
[1] Shandong University,Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine
[2] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Pediatrics, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital
[3] The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital,Department of Clinical Pharmacy, Clinical Trial Center
[4] Shandong Engineering and Technology Research Center for Pediatric Drug Development,Division of Clinical Pharmacology
[5] Shandong Medicine and Health Key Laboratory of Clinical Pharmacy,Departments of Pediatrics, Pharmacology and Physiology, Genomics and Precision Medicine, School of Medicine and Health Sciences
[6] Children’s National Hospital,Department of Paediatric Pharmacology and Pharmacometrics, University Children’s Hospital Basel
[7] George Washington University,Department of Clinical Pharmacy, School of Pharmaceutical Sciences
[8] University of Basel,undefined
[9] Shandong University,undefined
来源：
Clinical Pharmacokinetics | 2022年 / 61卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：71 / 81
页数：10
相关论文
共 50 条
  • [41] Minimal Residual Disease Eradication by Azacitidine Maintenance in a Patient with Core-Binding Factor Acute Myeloid Leukemia
    Yucel, Orhan Kemal
    Alemdar, Mustafa Serkan
    Atas, Unal
    Undar, Levent
    CHEMOTHERAPY, 2021, 65 (5-6) : 166 - 170
  • [42] Is age just a number? Intensive therapy for core-binding factor acute myeloid leukemia in older adults
    George, Benson M.
    Luskin, Marlise R.
    HAEMATOLOGICA, 2025, 110 (03) : 543 - 545
  • [43] Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801
    Marcucci, Guido
    Geyer, Susan
    Laumann, Kristina
    Zhao, Weiqiang
    Bucci, Donna
    Uy, Geoffrey L.
    Blum, William
    Eisfeld, Ann-Kathrin
    Pardee, Timothy S.
    Wang, Eunice S.
    Stock, Wendy
    Kolitz, Jonathan E.
    Kohlschmidt, Jessica
    Mrozek, Krzysztof
    Bloomfield, Clara D.
    Stone, Richard M.
    Larson, Richard A.
    BLOOD ADVANCES, 2020, 4 (04) : 696 - 705
  • [44] Single Institution Observational Study of Risk-Adapted Therapy for Children with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
    Hu, Yixin
    Gao, Li
    Xiao, Peifang
    He, Hailong
    Wang, Yi
    Fan, Liyan
    Cheng, Shengqin
    Ling, Jing
    Li, Jie
    Fan, Junjie
    Yao, Yanhua
    Ding, Xin
    Pan, Jian
    Lu, Jun
    Ribeiro, Raul C.
    Hu, Shaoyan
    BLOOD, 2022, 140 : 11809 - 11809
  • [45] Intensive Induction Chemotherapy with or without Gemtuzumab Ozogamicin Among Patients with Core-Binding Factor Acute Myeloid Leukemia
    Rojek, Alexandra E.
    McCormick, Benjamin J.
    Cwykiel, Joanna
    Odetola, Oluwatobi
    Abaza, Yasmin
    Achar, Rohan
    Shallis, Rory M.
    Bradshaw, Danielle
    Standridge, Meaghan
    Kota, Vamsi K.
    Badar, Talha
    Patel, Anand Ashwin
    BLOOD, 2023, 142
  • [46] An ETV6::NTRK3 fusion transcript in a core-binding factor acute myeloid leukemia
    Coster, Lucie
    Huguet, Francoise
    Canali, Alban
    Rieu, Jean-Baptiste
    Mansat-De Mas, Veronique
    EJHAEM, 2023, 4 (03): : 867 - 868
  • [47] Addition of Single Dose Gemtuzumab Ozogamicin to Intensive Induction Chemotherapy in Core-Binding Factor Acute Myeloid Leukemia
    Bourne, Garrett
    Diebold, Kendall
    Espinoza-Gutarra, Manuel
    Al-Kadhimi, Zaid
    Bachiashvili, Kimo
    Rangaraju, Sravanti
    Vachhani, Pankit
    Bhatia, Ravi
    Jamy, Omer
    BLOOD, 2023, 142
  • [48] RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia
    Kim, TaeHyung
    Moon, Joon Ho
    Ahn, Jae-Sook
    Ahn, Seo-Yeon
    Jung, Sung-Hoon
    Yang, Deok-Hwan
    Lee, Je-Jung
    Shin, Myung-Geun
    Choi, Seung Hyun
    Lee, Ja-yeon
    Tyndel, Marc S.
    Lee, Hui Young
    Kim, Kyoung Ha
    Cai, Yu
    Lee, Yoo Jin
    Sohn, Sang Kyun
    Min, Yoo Hong
    Cheong, June-Won
    Kim, Hyeoung-Joon
    Zhang, Zhaolei
    Kim, Dennis Dong Hwan
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [49] Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia
    Bourne, Garrett
    Diebold, Kendall
    Espinoza-Gutarra, Manuel
    Al-Kadhimi, Zaid
    Bachiashvili, Kimo
    Rangaraju, Sravanti
    Vachhani, Pankit
    Bhatia, Ravi
    Jamy, Omer
    LEUKEMIA RESEARCH, 2024, 139
  • [50] RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia
    TaeHyung Kim
    Joon Ho Moon
    Jae-Sook Ahn
    Seo-Yeon Ahn
    Sung-Hoon Jung
    Deok-Hwan Yang
    Je-Jung Lee
    Myung-Geun Shin
    Seung Hyun Choi
    Ja-yeon Lee
    Marc S. Tyndel
    Hui Young Lee
    Kyoung Ha Kim
    Yu Cai
    Yoo Jin Lee
    Sang Kyun Sohn
    Yoo Hong Min
    June-Won Cheong
    Hyeoung-Joon Kim
    Zhaolei Zhang
    Dennis Dong Hwan Kim
    Scientific Reports, 10
12345